MOTS-C

Research protocols vary significantly: Standard 20-day cycles use 5 mg subcutaneously every 5 days (total 20 mg per cycle), repeated 4 times yearly. Extended 30-day protocols use 10 mg weekly for 4 weeks (40 mg total), repeated within 6 months. Maximum protocols involve 5 mg three times weekly for 4-6 weeks (60-90 mg total) or 10 mg weekly for 10 weeks (100 mg total). Animal studies used 0.5-15 mg/kg/day intraperitoneally or subcutaneously.

Since MOTS-C isn't approved for human use, there are no official dosing guidelines. Researchers studying it have used different amounts and schedules - some give small doses every few days, others give larger doses weekly. The key is that this is all experimental, and what works in animals might not be safe for humans. Any use would need careful medical supervision.

MOTS-C is typically administered via subcutaneous injection using insulin-type syringes. Injection sites include abdomen, thigh, or upper arm with site rotation to prevent tissue damage. Research protocols suggest injection timing is flexible (morning or evening), independent of meals. Reconstitution requires bacteriostatic water, with prepared solutions stable for 14-21 days when refrigerated. Proper sterile technique is essential to prevent infection.

MOTS-C is typically administered via subcutaneous injection using insulin-type syringes. Injection sites include abdomen, thigh, or upper arm with site rotation to prevent tissue damage. Research protocols suggest injection timing is flexible (morning or evening), independent of meals. Reconstitution requires bacteriostatic water, with prepared solutions stable for 14-21 days when refrigerated. Proper sterile technique is essential to prevent infection.

Injection Protocol

• •Subcutaneous injection per protocol
• •Rotate injection sites
• •Consistent daily timing
• •Follow protocol guidelines

Monitoring Schedule

• •Regular progress monitoring
• •Health parameter monitoring
• •Laboratory monitoring
• •Safety monitoring